CANBRIDGE-B (01228.HK): Two Rare Disease Drugs Join First Commercial Insurance Cost Table
NewTimeSpace News: On 16 November 2026, CANbridge Pharmaceuticals Inc. (stock code: 1228) published a voluntary announcement that two of its products, velaglucerase alfa for injection and maralixibat oral solution, have been included in the first industry edition of the commercial health insurance drug cost table issued by the China Association of Actuaries on 10 November 2026.
The table covers 117 drugs across oncology, rare diseases, chronic diseases and other therapeutic areas to strengthen the pricing basis for innovative drug coverage. The two products cover three rare disease indications: Gaucher disease, Alagille syndrome and progressive familial intrahepatic cholestasis, which is expected to help rare disease patients ease their medication burden through commercial insurance.
The enzyme replacement therapy was approved by the National Medical Products Administration on 13 May 2025 as China's first self-developed long-term enzyme replacement therapy for patients aged 12 and above with type I and type III Gaucher disease. The Company holds worldwide proprietary development and commercialisation rights, has entered its first overseas market in North Africa, and is running a registrational trial to extend use to children aged two to under 12.
The oral solution is China's first product approved for Alagille syndrome and progressive familial intrahepatic cholestasis in patients aged three months and above. It was launched in mainland China in 2024, has been included in 64 cities' supplementary medical insurance schemes covering 299 million people, and was approved by Taiwan, China's National Health Insurance Administration on 14 August 2026, effective 1 September 2026.
- Fullgoal Hang Seng HK High Dividend ETF (03031.HK) Down 1.54% as Hong Kong Stocks Slide
- PINESTONE (00804.HK): Appoints Wu Yuanzheng as AI Business GM
- ALPHA PRO HLDGS (00948.HK): Clarifies 56.62M Excess Rights Shares
- EDDING GENOR (06998.HK): GB268 Wins NMPA Nod for NSCLC, BTC Trials
- HENLIUS (02696.HK): NMPA Clears HLX105 Phase 1 Solid Tumour IND